Panic Disorder

7
Pipeline Programs
3
Companies
5
Clinical Trials
4
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
6
Early DiscoveryClinical DevelopmentMarket

On Market (4)

Approved therapies currently available

UP
KEPPRAApproved
levetiracetam
UCB Pharma
oral1999
UP
KEPPRA XRApproved
levetiracetam
UCB Pharma
oral2008
U
LEVETIRACETAMApproved
levetiracetam
Unknown Company
oral2012
U
SPRITAMApproved
levetiracetam
Unknown Company
oral2015

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
2 programs
2
alprazolam XRPhase 41 trial
sertralinePhase 41 trial
Active Trials
NCT00634790Terminated49Est. Oct 2004
NCT00677352Completed321Est. Feb 2010
UP
UCB PharmaBelgium - Brussels
1 program
1
1
levetiracetamPhase 31 trial
Active Trials
NCT00279617Completed15Est. Mar 2009
Jerusalem Pharmaceuticals
Jerusalem PharmaceuticalsIsrael - Ramallah
2 programs
CBT- both internet and face to faceN/A1 trial
ICBT for panic and depressionN/A1 trial
Active Trials
NCT04029740Unknown80Est. Dec 2021
NCT04659577Completed130Est. Jan 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Pfizersertraline
Pfizeralprazolam XR
UCB Pharmalevetiracetam
Jerusalem PharmaceuticalsCBT- both internet and face to face
Jerusalem PharmaceuticalsICBT for panic and depression

Clinical Trials (5)

Total enrollment: 595 patients across 5 trials

A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder

Start: May 2008Est. completion: Feb 2010321 patients
Phase 4Completed
NCT00634790Pfizeralprazolam XR

A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks

Start: May 2004Est. completion: Oct 200449 patients
Phase 4Terminated

Levetiracetam Treatment of Panic Disorder and Lactate-Induced Panic Attacks

Start: Jan 2006Est. completion: Mar 200915 patients
Phase 3Completed
NCT04029740Jerusalem PharmaceuticalsCBT- both internet and face to face

Exosomal microRNAs as a Biomarker in Panic Disorder and in Response to CBT

Start: Mar 2019Est. completion: Dec 202180 patients
N/AUnknown
NCT04659577Jerusalem PharmaceuticalsICBT for panic and depression

Attitudes of Professionals and the General Public in Israel Regarding ICBT

Start: Nov 2016Est. completion: Jan 2022130 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space